Mycoplasma hominis (MH) and Ureaplasma species (Usp), commonly found in the lower urogenital tract, have been associated with various urogenital infections. This study aimed to estimate the prevalence and antimicrobial susceptibility trend of MH and Usp in female patients and to evaluate the risk factors for the acquisition of pristinamycin-resistant mycoplasma.
Endocervical swab specimens obtained between March 2016 and December 2018 were analyzed using a Mycoplasma IST2 Kit. Because pristinamycin and josamycin are not available in Korea, we conducted an age- and date-matched case–control study to evaluate the risk factors for the acquisition of pristinamycin-resistant isolates.
Among 4,035 specimens, 1,589 (39.4%) cases were shown positive results of genital mycoplasma, which included 49 (3.1%) cases of MH, 1,243 (78.2%) cases of Usp, and 297 (18.7%) cases of both MH and Usp, respectively. Based on antimicrobial susceptibility tests, the antibiotic susceptible rate of both MH and Usp to pristinamycin decreased annually during the study period (100%, 97.1%, and 87.3% for 2016, 2017, and 2018, respectively, p<0.001). According to a multivariate analysis, josamycin resistance (odds ratio, 7.18; 95% confidence interval, 1.20 to 43.00; p=0.027) and coinfection (odds ratio, 145.38; 95% confidence interval, 21.80 to 3017.23; p<0.001) with Candida species were independent risk factors for the acquisition of pristinamycin-resistant isolates.
Antibiotic-resistant genital mycoplasmas have been gradually increasing annually. Nationwide surveillance, proper antibiotic stewardship, and appropriate culture-based treatment strategies are required to control this upcoming threat.